A new JAMA case report described how amyloid clearance after amyloid-targeting therapy in Alzheimer’s disease correlates with reductions in subsequent neuropathologic changes. The analysis focuses on where amyloid removal was extensive and links that signal to later disease pathology, supporting the idea that amyloid burden aligns with downstream progression. In parallel, conference coverage around AAIC highlighted tau as a central focus for Alzheimer’s research, underscoring the field’s shift to combining amyloid and tau biology in translational endpoints and diagnostics. While the report’s details are case-based, it provides mechanistic support for therapy-related biomarker readouts. For drug developers, the practical implication is that clearance patterns may provide a more granular view of biological effect than a single averaged biomarker measurement.